Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
Authors:
Open Access
- 7 February 2012
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (6) , 1196-1204
Abstract
Epithelial mesenchymal transition (EMT) is known to be associated with chemoresistance as well as increased invasion/metastasis. However, the relationship between EMT and resistance to an epidermal growth factor receptor (EGFR) -targeting drug in head and neck squamous cell carcinoma (HNSCC) remains unknown. In this study, we investigated the acquisition of EMT by gefitinib in HNSCC cell line (UMSCC81B). We isolated fibroblastoid variant (81B-Fb) from gefitinib-resistant UMSCC81B-GR3 cells obtained after increasing the doses of gefitinib treatment in vitro and examined EMT and its underlying mechanism. 81B-Fb cells exhibited fibroblast-like morphology, increased motility, loss of E-cadherin, acquisition of vimentin and snail expression. In 81B-Fb cells, downregulation of EGFR, which is mediated by increased ubiquitination, and activation of downstream protein kinase B (Akt), glycogen synthase kinase-beta (GSK-3β) signalling and upregulation of snail expression were observed compared with UMSCC81B cells. LY294002, but not U0126, suppressed foetal bovine serum or heregulin-β1-induced phosphorylation of Akt/GSK-3β and snail expression together with the inhibition of 81B-Fb cell motility. Furthermore, forced expression of EGFR resulted in partial restoration of gefitinib sensitivity and reversal of EMT. These results suggest that EMT in the gefitinib-resistant cells is mediated by the downregulation of EGFR and compensatory activation of Akt/GSK-3β/snail pathway.Keywords
This publication has 30 references indexed in Scilit:
- Epithelial–mesenchymal transition in cancer development and its clinical significanceCancer Science, 2010
- Prognostic Significance of Epidermal Growth Factor Receptor Phosphorylation and Mutation in Head and Neck Squamous Cell CarcinomaThe Oncologist, 2009
- Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung CancerPathology and Oncology Research, 2009
- The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancerBiochemical Journal, 2008
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnnals of Oncology, 2008
- Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinomaMolecular Cancer Therapeutics, 2007
- Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma CellsClinical Cancer Research, 2006
- Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patientsBritish Journal of Cancer, 2005
- Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activationOncogene, 2002
- Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinasesNature, 1997